3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
1
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
Cyclophosphamide
517
Bevacizumab
488
Carboplatin
424
pembrolizumab
388
Paclitaxel
385
Gemcitabine
372
Cisplatin
366
Docetaxel
323
Rituximab
316
Radiotherapy
296
Nivolumab
247
Doxorubicin
243
Dexamethasone
240
Fluorouracil
225
Capecitabine
214
Oxaliplatin
211
Erlotinib Hydrochloride
206
fludarabine phosphate
201
Etoposide
188
Cetuximab
186
Lenalidomide
177
Pemetrexed
176
Bortezomib
174
Trastuzumab
173
Filgrastim
171
fludarabine
166
Prednisone
166
Leucovorin
166
Cytarabine
166
Irinotecan
161
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Has results
×
Cantharidin
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts